Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 23 09:44AM ET
19.50
Dollar change
0.00
Percentage change
0.00
%
Index- P/E- EPS (ttm)- Insider Own29.61% Shs Outstand43.12M Perf Week-13.06%
Market Cap840.84M Forward P/E- EPS next Y-4.00 Insider Trans19.27% Shs Float30.35M Perf Month-24.18%
Income- PEG- EPS next Q-0.84 Inst Own3.25% Short Float4.77% Perf Quarter-
Sales- P/S- EPS this Y96.35% Inst Trans- Short Ratio2.89 Perf Half Y-
Book/sh-3.05 P/B- EPS next Y-22.14% ROA- Short Interest1.45M Perf Year-
Cash/sh1.33 P/C14.61 EPS next 5Y- ROE- 52W Range17.76 - 35.06 Perf YTD-35.00%
Dividend Est.- P/FCF- EPS past 5Y- ROI- 52W High-44.38% Beta-
Dividend TTM- Quick Ratio3.05 Sales past 5Y-37.90% Gross Margin- 52W Low9.80% ATR (14)1.51
Dividend Ex-Date- Current Ratio3.05 EPS Y/Y TTM- Oper. Margin- RSI (14)33.44 Volatility8.95% 7.46%
Employees96 Debt/Eq0.18 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price42.75
Option/ShortYes / Yes LT Debt/Eq0.13 EPS Q/Q- Payout- Rel Volume0.08 Prev Close19.50
Sales Surprise- EPS Surprise-2819.81% Sales Q/Q- EarningsMar 26 AMC Avg Volume500.37K Price19.50
SMA20-13.44% SMA50-25.00% SMA200-25.23% Trades Volume3,304 Change0.00%
Date Action Analyst Rating Change Price Target Change
Mar-04-24Initiated Wells Fargo Overweight $44
Mar-04-24Initiated Morgan Stanley Overweight $40
Mar-04-24Initiated Leerink Partners Outperform $48
Mar-04-24Initiated JP Morgan Overweight $39
Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company. It develops treatments and potential cures for serious autoimmune diseases. The company was founded in June 2018 and is headquartered in Emeryville, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GILEAD SCIENCES, INC.10% OwnerFeb 12 '24Buy22.00910,00020,020,0004,126,119Feb 13 05:48 PM
Northpond Ventures III GP, LLCFormer 10% OwnerFeb 12 '24Buy22.00450,0009,900,000450,000Feb 12 05:51 PM
Bain Capital Life Sciences Inv10% OwnerFeb 12 '24Buy22.00450,0009,900,0003,163,868Feb 14 05:26 PM
Vida Ventures, LLC10% OwnerFeb 12 '24Buy22.00253,1365,568,992252,553Feb 14 07:04 PM
Last Close
Apr 23 09:44AM ET
4.66
Dollar change
+0.11
Percentage change
2.49
%
ANNX Annexon Inc daily Stock Chart
IndexRUT P/E- EPS (ttm)-1.78 Insider Own18.48% Shs Outstand105.09M Perf Week-8.93%
Market Cap489.54M Forward P/E- EPS next Y-1.64 Insider Trans1.63% Shs Float85.66M Perf Month-31.50%
Income-134.24M PEG- EPS next Q-0.34 Inst Own66.36% Short Float4.19% Perf Quarter-0.68%
Sales0.00M P/S- EPS this Y13.88% Inst Trans11.81% Short Ratio2.27 Perf Half Y163.18%
Book/sh3.20 P/B1.46 EPS next Y-7.79% ROA-46.07% Short Interest3.59M Perf Year-16.96%
Cash/sh2.47 P/C1.88 EPS next 5Y38.60% ROE-55.73% 52W Range1.57 - 8.40 Perf YTD2.61%
Dividend Est.- P/FCF- EPS past 5Y-29.69% ROI-47.99% 52W High-44.54% Beta1.30
Dividend TTM- Quick Ratio14.72 Sales past 5Y0.00% Gross Margin- 52W Low196.71% ATR (14)0.52
Dividend Ex-Date- Current Ratio14.72 EPS Y/Y TTM37.91% Oper. Margin0.00% RSI (14)36.06 Volatility10.11% 10.01%
Employees71 Debt/Eq0.13 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price15.17
Option/ShortYes / Yes LT Debt/Eq0.12 EPS Q/Q24.94% Payout- Rel Volume0.26 Prev Close4.55
Sales Surprise- EPS Surprise17.34% Sales Q/Q- EarningsMar 26 AMC Avg Volume1.58M Price4.66
SMA20-22.40% SMA50-18.12% SMA20025.18% Trades Volume34,996 Change2.49%
Date Action Analyst Rating Change Price Target Change
Mar-01-24Upgrade JP Morgan Neutral → Overweight $11
Dec-21-23Upgrade BofA Securities Neutral → Buy $4 → $6
Oct-30-23Initiated Wells Fargo Overweight $11
May-26-23Downgrade BofA Securities Buy → Neutral $8 → $3
May-25-23Downgrade JP Morgan Overweight → Neutral $19 → $9
Sep-16-22Initiated Jefferies Buy $12
Sep-09-22Initiated BTIG Research Buy $15
Nov-30-21Initiated H.C. Wainwright Buy $40
Sep-23-21Initiated Cantor Fitzgerald Overweight $40
Jan-26-21Initiated Needham Buy $37
Apr-17-24 09:40AM
Apr-16-24 04:05PM
09:00AM
Apr-14-24 12:52PM
Apr-10-24 06:15PM
08:00AM Loading…
Apr-03-24 08:00AM
Apr-01-24 12:00PM
09:55AM
Mar-28-24 05:31AM
Mar-26-24 08:53PM
04:05PM
Mar-18-24 04:05PM
Mar-14-24 08:40AM
Mar-12-24 02:51PM
Feb-27-24 08:00AM
08:00AM Loading…
Feb-21-24 08:00AM
Feb-20-24 04:05PM
Feb-13-24 01:10PM
Jan-18-24 09:40AM
Jan-17-24 11:06AM
Jan-07-24 08:00PM
Dec-27-23 06:30AM
Dec-20-23 05:27PM
05:10PM
05:08PM
Dec-18-23 04:01PM
Nov-22-23 04:01PM
Nov-14-23 07:20PM
Nov-13-23 06:30AM
Nov-09-23 06:30AM
06:30AM Loading…
Oct-24-23 06:30AM
Oct-18-23 04:01PM
Oct-10-23 06:30AM
Sep-19-23 06:30AM
Sep-18-23 04:01PM
Sep-08-23 09:35AM
Aug-07-23 06:30AM
Aug-02-23 04:01PM
Jul-30-23 12:00PM
Jul-27-23 06:30AM
Jul-24-23 06:30AM
Jun-14-23 08:36AM
May-30-23 10:40AM
May-26-23 03:05AM
May-25-23 11:52AM
10:12AM
May-24-23 04:01PM
May-16-23 04:01PM
May-08-23 04:01PM
Apr-11-23 06:30AM
Mar-25-23 08:04AM
Mar-06-23 06:30AM
Feb-27-23 06:30AM
Feb-16-23 04:05PM
Feb-12-23 07:35AM
Jan-17-23 04:30PM
Jan-08-23 09:00AM
Jan-06-23 06:30AM
Jan-04-23 06:30AM
Dec-01-22 09:55AM
Nov-21-22 06:13AM
Nov-17-22 04:01PM
Nov-15-22 09:55AM
Nov-03-22 06:30AM
Oct-18-22 04:01PM
Oct-11-22 07:01AM
Sep-16-22 04:01PM
Sep-01-22 05:56PM
Aug-17-22 04:05PM
Aug-08-22 04:01PM
Jul-11-22 06:25PM
Jul-08-22 07:00AM
Jun-07-22 12:19PM
06:30AM
Jun-02-22 06:30AM
Jun-01-22 07:30AM
May-09-22 04:01PM
May-05-22 06:30AM
Apr-21-22 06:02AM
Apr-18-22 10:35AM
Apr-07-22 06:30AM
Apr-04-22 06:30AM
Mar-03-22 04:01PM
Mar-01-22 04:01PM
Feb-28-22 06:30AM
Jan-20-22 06:30AM
Jan-05-22 05:10PM
06:33AM
Jan-04-22 04:05PM
06:30AM
Dec-31-21 08:30AM
Dec-13-21 09:00AM
Nov-30-21 05:24AM
Nov-28-21 11:17AM
Nov-09-21 04:01PM
Oct-19-21 06:38AM
Oct-04-21 10:49AM
06:30AM
Sep-23-21 06:30AM
Sep-20-21 06:30AM
Annexon, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain. It offers drugs that control or target huntington's and alzheimer's disease, multiple sclerosis, glaucoma, parkinson's disease, and spinal muscular atrophy. The company was founded by Ben Barres and Arnon Rosenthal on March 3, 2011 and is headquartered in Brisbane, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Carson William H.DirectorApr 08 '24Buy6.073,20019,4113,200Apr 10 07:17 PM
Yednock TedEVP & CHIEF INNOVATION OFFICERFeb 20 '24Sale5.512,60414,34872,471Feb 21 04:31 PM
Lew JenniferEVP & CHIEF FINANCIAL OFFICERFeb 20 '24Sale5.532,59314,33982,058Feb 21 04:31 PM
Overdorf MichaelEVP & CHIEF BUSINESS OFFICERFeb 20 '24Sale5.481,95110,69185,641Feb 21 04:31 PM
Love DouglasPRESIDENT AND CEOFeb 12 '24Sale5.545,78232,032196,121Feb 14 07:56 PM
Yednock TedEVP & CHIEF INNOVATION OFFICERFeb 12 '24Sale5.541,81010,02736,075Feb 14 07:52 PM
Lew JenniferEVP & CHIEF FINANCIAL OFFICERFeb 12 '24Sale5.541,80910,02245,651Feb 14 07:54 PM
Overdorf MichaelEVP & CHIEF BUSINESS OFFICERFeb 12 '24Sale5.531,3497,46048,592Feb 14 07:59 PM
Yednock TedEVP & Chief Innovation OfficerDec 27 '23Option Exercise1.6321,00034,17621,000Dec 29 04:12 PM
Yednock TedEVP & Chief Innovation OfficerDec 27 '23Sale4.5221,00094,9660Dec 29 04:12 PM
Satter Muneer ADirectorDec 26 '23Buy2.88350,0001,008,0007,406,024Dec 28 04:30 PM
Lew JenniferEVP & Chief Financial OfficerJul 11 '23Sale3.841,0574,05547,460Jan 23 04:57 PM
Overdorf MichaelEVP & Chief Business OfficerJul 11 '23Sale3.849783,75245,802Jan 23 04:58 PM
Bain Capital Life Sciences Inv10% OwnerMay 25 '23Buy2.13300,000639,7205,701,926May 30 09:54 PM